MDCO TARG – This deal is pretty far removed from MDCO’s raison d’etre, which has been drugs for the cath lab and the ER. I take the deal to mean that MDCO is increasingly resigned to losing patent protection on Angiomax in 2010, which is five years earlier than it should have happened.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”